Advancing Antibody Drug Conjugates (ADCs) With Expertise In Payloads And Linkers

SK pharmteco’s ADC payload and linker solutions integrate scale, safety, and deep scientific expertise to support even the most technically demanding programs. Our right-sized, purpose-built facilities incorporate advanced containment and engineering controls, ensuring operator protection and full regulatory compliance across development, scale-up, and commercial manufacturing. This infrastructure enables safe handling of highly potent compounds while maintaining operational flexibility and efficiency.

With more than 20 years of experience in high-potency API (HPAPI) development and over a decade supplying commercial-scale linkers for antibody–drug conjugates (ADCs), our teams bring proven expertise in managing complex, multi-step synthetic routes. We specialize in addressing the unique challenges of ADC payloads and linkers, including tight impurity control, robust process optimization, and seamless technology transfer from early development through commercialization.

Complementing this foundation is our world-class chromatography capability, which supports advanced purification strategies and consistently delivers payloads and linkers of exceptional purity and reproducibility. This integrated technical strength, combined with global project management and supply reliability, positions SK pharmteco as a trusted partner in advancing ADC therapeutics from concept to commercial launch.

This white paper outlines best practices in ADC payload and linker development and highlights two case studies demonstrating how SK pharmteco’s global team optimized complex linker–payload processes and engineered novel synthetic routes to accelerate delivery timelines.